January 23, 2018 07:39 AM EST
R&D

Lin­ing up against ri­vals, Am­gen and No­var­tis build a block­buster case for their CGRP mi­graine drug

John Carroll

Editor & Founder

Am­gen $AMGN and its part­ners at No­var­tis $NVS rolled out a fresh batch of solid­ly pos­i­tive da­ta from the lat­est Phase III study of their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Unit­ed­Health Group CEO An­drew Wit­ty steps down

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

HHS fo­cus­es on 'trans­paren­cy' in third-round IRA ne­go­ti­a­tion guid­ance

Arc­turus to pri­or­i­tize mR­NA ther­a­peu­tics in bid to boost rare dis­ease pro­grams

A service from the Financial Times